Institutional-grade
investment analysis.
The same rigor a Sanofi BD team runs on an acquisition target — DCF, rNPV, fundamental analysis, and M&A reverse-engineering — applied to the positions you actually hold. Built for individual and family-office investors, delivered through the CatalystIQ terminal.
The methodology institutions use, productized.
Most retail tools give you price charts and headlines. CatalystIQ gives you the valuation engines a corporate development team would actually run — discounted cash flow, risk-adjusted NPV with pipeline auto-fill, Monte Carlo tail-risk analysis, and a comparable-transaction database calibrated against real closed deals. It is the MCS Advisory product line that brings institutional methodology to investors who were never given access to it.
What the terminal does.
Sangamo (SGMO) positioning vs. 12 biotech M&A transactions.
A worked example of the methodology: a 12-deal biotech M&A transaction database covering $50B+ in aggregate deal value, used to calibrate SGMO's positioning via rNPV capture rates rather than premium-to-current. The full note is on the Insights page.
Free tier, plus Pro.
Public launch comes July 2026. A free tier covers core analysis; the Pro tier ($14.99/month or $149/year) unlocks the advanced engines — Monte Carlo, rNPV, and the Portfolio Builder — with a 7-day free trial.
Want institutional rigor on your own positions?
Explore CatalystIQ directly, or reach out for a confidential conversation about family-office research engagements.
Visit CatalystIQ →